Get the Stockscreener App
1.39
0.00%
0.00
After Hours:
1.37
-0.02
-1.44%
Igm Biosciences Inc stock is traded at $1.39, with a volume of 244.29K.
It is up +0.00% in the last 24 hours and up +0.72% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$1.39
Open:
$1.36
24h Volume:
244.29K
Relative Volume:
0.55
Market Cap:
$83.09M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-0.3819
EPS:
-3.64
Net Cash Flow:
$-176.15M
1W Performance:
+2.96%
1M Performance:
+0.72%
6M Performance:
-87.80%
1Y Performance:
-86.03%
1-Day Range:
$1.34
$1.424
1-Week Range:
$1.26
$1.425
52-Week Range:
$1.25
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.39 | 83.09M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-10-25 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-10-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-10-25 | Downgrade | Stifel | Buy → Hold |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks
IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India
IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com UK
IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
IGM to slash 73% of workforce, halt two drug programs - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) PT at $5.50 - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus Price Target from Analysts - Defense World
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround - Nasdaq
Impressive Stock Surge: IGM Biosciences, XTI Aerospace and More See Major Gains – Market - HPBL
Impressive Stock Gains Across Multiple Sectors: IGM Biosciences, XTI Aerospace, and More Surge - HPBL
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc.IGMS - Longview News-Journal
IGM Biosciences stock plunges to 52-week low of $1.59 By Investing.com - Investing.com Canada
Why Is IGM Biosciences Inc (NASDAQ: IGMS) Falling? - Stocks Register
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):